SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF

Prospective, Single-cohort, Observational Clinical Study Evaluating the Rate of Achieving SVR12 in Patients With Chronic Hepatitis C Genotype 3 With Fibrosis Stage F0-F2 Who Received Ravidasvir + Sofosbuvir Therapy.

This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care.

Only patients who start this treatment, meet the study's eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-drug therapy.

After 8 weeks of treatment, researchers will check how many patients have cleared the virus from their blood. Those who achieve this response will continue to be followed for another 4 and 12 weeks after treatment to see if the virus remains undetectable.

Study Overview

• Status: Active, not recruiting
• Conditions: Viral Hepatitis C

Detailed Description

An observational, prospective, single-cohort study will be conducted in patients with chronic hepatitis C virus infection of genotype 3 and fibrosis stage F0-F2 according to the METAVIR score based on liver elastography data, who have initiated antiviral therapy with ravidasvir and sofosbuvir as part of routine clinical practice.

Patients who have initiated antiviral therapy with ravidasvir and sofosbuvir, meet the inclusion criteria, and have signed informed consent for the use of their data in scientific research will be enrolled in the study. Patients will be followed in the clinic in accordance with routine medical practice during the course of ravidasvir and sofosbuvir antiviral therapy.

After 8 weeks of therapy, the rate of viral eradication in peripheral blood will be determined. Patients who achieve a virological response will continue to be followed to assess the maintenance of virological response at 4 and 12 weeks after completion of antiviral therapy.

• Study Type: Observational
• Enrollment (Actual): 30

Contacts and Locations

Study Locations

• Russia
  • Moscow, Russia, 125008
    • Center of Target Therapy LLC.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with chronic hepatitis C virus infection genotype 3 with fibrosis stage F0-F2 were selected for this non-interventional study. These patients represent an important group with a high probability of successful therapy response and relatively low risk of complications, making them ideal candidates for studying the efficacy and safety of a short-term treatment regimen with ravidasvir and sofosbuvir. A similar patient population showed a high rate of sustained virological response (93.42%) in the EASE clinical trial (NCT05757700) with an 8-week therapy regimen. Despite the presence of significant data on treatment of chronic hepatitis C overall, detailed descriptions of disease epidemiology depending on virus genotype, fibrosis stage, and treatment efficacy in patients at early disease stages in real clinical practice are limited.

Description

Inclusion Criteria:

• Patient informed consent for the collection and use of data in scientific research.
• Diagnosed chronic hepatitis C (genotype 3).
• Fibrosis stage F0-F2 according to METAVIR, confirmed by liver biopsy or liver elastography (results of performed studies must be no older than 3 months at the start of antiviral therapy).
• Signed informed consent.
• Age ≥18 years.
• Antiviral therapy with ravidasvir and sofosbuvir initiated as part of routine clinical practice.

Exclusion Criteria:

• Significant concomitant liver diseases considered relevant by the investigator (hepatitis B, hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma).
• Presence of other active viral infections (e.g., hepatitis B, HIV).
• If the patient has received other antiviral treatment for hepatitis C within the last 6 months.
• Pregnancy or breastfeeding.
• Alcohol or drug dependence that may interfere with adherence to the treatment regimen.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the rate of achieving sustained virological response (SVR12)	Absence of detectable hepatitis C virus (HCV) RNA in a patient's blood 12 weeks after completing antiviral treatment	20 weeks after enrollment to the study (8 weeks of antiviral treatment + 12 week of post-treatment follow up)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the rate of achieving aviremia 4 weeks after completion of antiviral therapy (SVR-4)	The absence of detectable hepatitis C virus (HCV) RNA in a patient's blood 4 weeks after completing antiviral treatment	12 weeks after enrollment (8 weeks of antiviral treatment + 4 weeks of post-treatment follow up)
Assessment of the dynamics of viral load changes during treatment	The amount of hepatitis C virus RNA present in a milliliter of a patient's blood (IU/mL).	At Week 4 after enrollment (therapy initiation), at Week 8 after enrollment (end of antiviral treatment), at Week 12 and Week 20 after enrollment (post-treatment follow up).
Assessment of the safety and tolerability of therapy.	The frequency and nature of side effects associated with the combination of ravidasvir and sofosbuvir.	20 weeks after enrollment (8 weeks of antiviral therapy and 12 weeks of post-treatment follow up)

Collaborators and Investigators

• Sponsor: Center of target therapy
• Investigators: Principal Investigator: Pavel Bogomolov, Prof., PhD, MD, Center of target therapy

Study record dates

Study Major Dates

• Study Start (Actual): September 17, 2025
• Primary Completion (Estimated): February 2, 2026
• Study Completion (Estimated): February 2, 2026

Study Registration Dates

• First Submitted: December 1, 2025
• First Submitted That Met QC Criteria: December 18, 2025
• First Posted (Actual): January 5, 2026

Study Record Updates

• Last Update Posted (Actual): January 5, 2026
• Last Update Submitted That Met QC Criteria: December 18, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Sofosbuvir; Ravidasvir
• Additional Relevant MeSH Terms: Blood-Borne Infections; Infections; RNA Virus Infections; Virus Diseases; Digestive System Diseases; Liver Diseases; Hepatitis, Viral, Human; Communicable Diseases; Flaviviridae Infections; Hepatitis; Hepatitis C
• Other Study ID Numbers: CTT-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No